Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1177-1187

  Weng, Qinjie ^a   Zhang, Jun ^a   Cao, Ji ^a   Xia, Qing ^b   Wang, Duoduo ^a   Hu, Yongzhou ^b   Sheng, Rong ^b   Wu, Honghai ^a   Zhu, Difeng ^a   Zhu, Hong ^a   He, Qiaojun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

4E BP1; Akt mTOR 4E BP1 signaling pathway; Hypoxia inducible factor 1 (HIF 1); Translational regulation

Indexed keywords

3 (4 BROMOPHENYL) 2 (ETHYLSULFONYL) 6 METHYLQUINOXALINE 1,4 DIOXIDE; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; Q 39; UNCLASSIFIED DRUG; VASCULOTROPIN; 3-(4-BROMOPHENYL)-2-(ETHYLSULFONYL)-6-METHYLQUINOXALINE-1,4-DIOXIDE; EIF4EBP1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; QUINOXALINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEADY STATE; TRANSLATION REGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856064603     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9462-y     Document Type: Article

References (30)

1. Sheng R, Xu Y, Weng QJ, Xia Q, He QJ, Yang B, Hu YZ (2007) Synthesis and cytotoxic activity of 3-phenyl-2-thio-quinoxaline 1, 4-dioxide derivatives in hypoxia and in normoxia. Drug Discov Ther 1:119-123
2. Weng Q, Wang D, Guo P, Fang L, Hu Y, He Q, Yang B (2008) Q39, a novel synthetic Quinoxaline 1, 4-Di-N-oxide compound with anticancer activity in hypoxia. Eur J Pharmacol 581:262-269
3. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8:S62-S67 (Pubitemid 34297081)
4. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677-684 (Pubitemid 36749216)
5. Fang J, Ding M, Yang L, Liu LZ, Jiang BH (2007) PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 19:2487-2497 (Pubitemid 47531929)
6. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD (2002) A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62:854-859 (Pubitemid 34126964)
7. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR (2001) Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 159:651-659 (Pubitemid 32751095)
8. Li XM, Tang ZY, Zhou G, Lui YK, Ye SL (1998) Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17:13-17 (Pubitemid 28215959)
9. Li ZD, Liu LZ, Shi X, Fang J, Jiang BH (2007) Benzo[a]pyrene-3, 6-dione inhibited VEGF expression through inducing HIF-1alpha degradation. Biochem Biophys Res Commun 357:517-523 (Pubitemid 46603161)
10. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr (2001) HIFá targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464
11. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54 (Pubitemid 32972036)
12. Beibei Fu, Xue J, Li Z, Shi X, Jiang B-H, Fang J (2007) Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis. Mol Cancer Ther 6:220-226 (Pubitemid 46206685)
13. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1 á expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545 (Pubitemid 30183422)
14. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004 (Pubitemid 32476461)
15. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxiainducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014
16. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127 (Pubitemid 43050086)
17. Topisirovic I, Ruiz-Gutierrez M, Borden KLB (2004) Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64:8639-8642 (Pubitemid 39552077)
18. Belozerov VE, Van Meir EG (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16:901-909 (Pubitemid 41416080)
19. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang B-H (2005) Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19:342-353 (Pubitemid 40316522)
20. Powis G, Kirkpatrick L (2004) Hypoxia inducible factor 1α as a cancer drug target. Mol Cancer Ther 3:647-654 (Pubitemid 39193744)
21. Dai M, Miao ZH, Ren X, Tong LJ, Yang N, Li T, Lin LP, Shen YM, Ding J (2009) MFTZ-1 reduces constitutive and inducible HIF-1alpha accumulation and VEGF secretion independent of its topoisomerase II inhibition. J Cell Mol Med, in press.
22. Li MH, Miao ZH, Tan WF, Yue JM, Zhang C, Lin LP, Zhang XW, Ding J (2004) Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res 10:8266-8274 (Pubitemid 40053386)
23. Hagen T, D'Amico G, Quintero M, Palacios-Callender M, Hollis V, Lam F, Moncada S (2004) Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol. Biochem Biophys Res Commun 322:923-929 (Pubitemid 39164441)
24. Nagasawa H, Mikamo N, Nakajima Y, Matsumoto H, Uto Y, Hori H (2003) Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway. Anticancer Res 23:4427-4434 (Pubitemid 37474896)
25. McKeown SR, Cowen RL, Williams KJ (2007) Bioreductive drugs: from concept to clinic. Clin Oncol 19:427-442 (Pubitemid 46995614)
26. Yoshiji H, Kuriyama S, Yoshii J, Yamazaki M, Kikukawa M, Tsujinoue H, Nakatani T, Fukui H (1998) Vascular endothelial growth factor tightly regulates in vitro development of murine hepatocellular carcinoma cells. Hepatology 28:1489-1496 (Pubitemid 28549117)
27. Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS (2003) Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 16:552-557 (Pubitemid 36718436)
28. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST (2003) Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellularcarcinoma. Cancer Res 63:3121-3126 (Pubitemid 36735862)
29. Lu L, Yang Z, Zhu B, Fang S, Yang X, Cai W, Li C, Ma JX, Gao G (2007) Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 257:97-106 (Pubitemid 47464701)
30. Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ (2008) A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxiainducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation. Eur J Pharmacol 592:41-47